Link to Scientific Article :
The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality
Date of Publication: April 2020
The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) causes significant mortality. It is therefore important to minimize the inflammatory response.